Executive SummaryIntegrated Genetics entered into license and development agreement with the German firm BASF for tissue-type plasminogen activator (tPA). The agreement calls for Integrated Genetics to produce tPA for clinical trials, expected to begin in 1986, and to research "other proteins" over a several year period. The firm indicated that BASF will market the final products through its Knoll subsidiary, in all parts of the world except Japan and the Far East, which are covered under a prior agreement with the Japanese firm, Toyobo.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.